BioCentury
ARTICLE | Company News

ODAC to review Phase IV commitments

October 11, 2005 12:39 AM UTC

FDA's Oncologic Drugs Advisory Committee will meet on Nov. 8 to review the status of Phase IV trials of seven products that were granted accelerated approval. The products include Doxil doxorubicin fr...